Tagged with GI

France Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study encompassing French startups in biotech, medtech and digital health.   France Biotech, the French association for innovation in healthcare, has…

Belgium While only Europe’s 34th biggest country by landmass and 13th by population, Belgium punches well above its weight in terms of key life sciences industry indicators, notably placing in the Top Five European countries for pharma R&D spending, pharma exports, and pharma imports. Made with Visme Infographic Maker   Made…

Belgium A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent study on the country’s clinical trial footprint.   Neuraxpharm completes its presence in Benelux by opening an affiliate in Brussels…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval in the US, Hungary’s windfall tax on pharma, Presage’s collaboration with Pure Biologics and Lithuania’s biotech ambitions.   Polpharma working…

UK A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding downturn and Gilead’s Yescarta approval from NICE.   Northern Ireland Medicines supply still ‘problematic and inefficient’ (BBC News) According to…

Japan Japan is known for its cutting-edge technology, innovative products, and world-class healthcare system. The pharmaceutical industry in Japan is no exception, with many leading companies making significant contributions to global health and wellness. Read on for a rundown of the top 10 Japanese pharmaceutical companies (based on market capitalisation in…

Global What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical capabilities and must-have skills for senior leaders, looking at the levers that drive customer-centric success in pharma and healthcare, and…

China One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19 jabs. The manufacturer of the world’s first inhaled COVID-19 vaccine, CanSinoBIO is also continuing to invest in mRNA technology in…

LatAm Latin America is a crucial region for medtech market leader Medtronic. Home to 20,000 of the company’s 95,000+ global workforce, 12 manufacturing plants, and ten commercial organisations, Medtronic LatAm grew by an impressive 24 percent last fiscal year and is becoming an increasingly important global revenue driver. The firm’s SVP…

China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration …   Pfizer CEO rules out generic…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

Europe Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the general pharmaceutical legislation and why it would prove unsustainable for smaller companies and…